Zhejiang Yatai Pharmaceutical Co Ltd (002370) — Working Capital to Net Assets Ratio
Zhejiang Yatai Pharmaceutical Co Ltd (002370) has a Working Capital to Net Assets ratio of 67.1% as of March 2026. Working capital of CN¥749.53 Million (current assets of CN¥858.06 Million minus current liabilities of CN¥108.53 Million) is measured against net assets of CN¥1.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Zhejiang Yatai Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Yatai Pharmaceutical Co Ltd Working Capital to Net Assets (2006–2025)
This chart shows how Zhejiang Yatai Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the ratio stands at 67.1%, reflecting working capital of CN¥749.53 Million against net assets of CN¥1.12 Billion CNY. Check Zhejiang Yatai Pharmaceutical Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Zhejiang Yatai Pharmaceutical Co Ltd (2006–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Yatai Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002370 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 66.6% | CN¥746.04 Million | CN¥1.12 Billion | CN¥898.27 Million | CN¥152.24 Million | ▲ +11.2 pp |
| 2024 | 55.4% | CN¥538.72 Million | CN¥972.18 Million | CN¥955.16 Million | CN¥416.44 Million | ▼ -81.2 pp |
| 2023 | 136.6% | CN¥793.38 Million | CN¥580.87 Million | CN¥955.18 Million | CN¥161.80 Million | ▼ -123.2 pp |
| 2022 | 259.8% | CN¥782.46 Million | CN¥301.22 Million | CN¥1.00 Billion | CN¥222.38 Million | ▲ +79.2 pp |
| 2021 | 180.5% | CN¥781.70 Million | CN¥432.96 Million | CN¥995.85 Million | CN¥214.15 Million | ▲ +31.7 pp |
| 2020 | 148.9% | CN¥983.32 Million | CN¥660.41 Million | CN¥1.27 Billion | CN¥291.52 Million | ▼ -57.8 pp |
| 2019 | 206.7% | CN¥1.31 Billion | CN¥633.06 Million | CN¥1.48 Billion | CN¥173.38 Million | ▲ +172.7 pp |
| 2018 | 34.1% | CN¥809.83 Million | CN¥2.38 Billion | CN¥1.49 Billion | CN¥678.61 Million | ▼ -5.7 pp |
| 2017 | 39.8% | CN¥906.63 Million | CN¥2.28 Billion | CN¥1.37 Billion | CN¥468.33 Million | ▼ -3.9 pp |
| 2016 | 43.7% | CN¥946.90 Million | CN¥2.17 Billion | CN¥1.21 Billion | CN¥264.31 Million | ▲ +31.2 pp |
| 2015 | 12.5% | CN¥99.44 Million | CN¥793.15 Million | CN¥852.37 Million | CN¥752.93 Million | ▼ -40.1 pp |
| 2014 | 52.7% | CN¥393.51 Million | CN¥747.31 Million | CN¥493.65 Million | CN¥100.13 Million | ▼ -3.7 pp |
| 2013 | 56.4% | CN¥400.32 Million | CN¥709.83 Million | CN¥492.01 Million | CN¥91.69 Million | ▲ +1.0 pp |
| 2012 | 55.4% | CN¥390.16 Million | CN¥703.94 Million | CN¥503.97 Million | CN¥113.81 Million | ▼ -7.4 pp |
| 2011 | 62.8% | CN¥467.97 Million | CN¥745.30 Million | CN¥594.30 Million | CN¥126.33 Million | ▼ -1.8 pp |
| 2010 | 64.6% | CN¥464.74 Million | CN¥719.95 Million | CN¥609.54 Million | CN¥144.79 Million | ▲ +48.3 pp |
| 2009 | 16.3% | CN¥37.35 Million | CN¥229.79 Million | CN¥249.27 Million | CN¥211.93 Million | ▼ -5.4 pp |
| 2008 | 21.7% | CN¥43.08 Million | CN¥198.69 Million | CN¥229.82 Million | CN¥186.74 Million | ▲ +27.8 pp |
| 2007 | -6.1% | CN¥-9.66 Million | CN¥157.93 Million | CN¥194.84 Million | CN¥204.51 Million | ▼ -23.8 pp |
| 2006 | 17.7% | CN¥25.57 Million | CN¥144.78 Million | CN¥202.72 Million | CN¥177.15 Million | — |